AKT1 and cancer: Capivasertib induced objective responses as a single agent in 20 % to 30 % of patients whose cancer had an AKT1 E17K mutation (Hyman et al., 2017; Kalinsky et al., 2021; Smyth et al., 2020), a mutation that is exceptionally uncommon in pediatric cancers (St.